ZFIN ID: ZDB-FISH-150901-17810
Fish name: hmgcs1vu57/vu57; vu16Tg
Genotype: hmgcs1vu57/vu57; vu16Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by hmgcs1vu57/vu57; vu16Tg
No data available
GENE EXPRESSION
Gene expression in hmgcs1vu57/vu57; vu16Tg
RNA expression No data available
PHENOTYPE
Phenotype in hmgcs1vu57/vu57; vu16Tg
Phenotype Conditions Figures
dorsal longitudinal fasciculus axon ensheathment in central nervous system decreased process quality, abnormal control Fig. 8 from Mathews et al., 2014
dorsal longitudinal fasciculus axon ensheathment in central nervous system process quality, normal chemical treatment: cholesterol Fig. 8 from Mathews et al., 2014
oligodendrocyte development process quality, abnormal control Fig. 5 from Mathews et al., 2014
spinal cord central nervous system myelination decreased occurrence, abnormal chemical treatment by environment: U0126 Fig. 6 from Mathews et al., 2016
spinal cord central nervous system myelination decreased occurrence, abnormal chemical treatment by environment: sirolimus Fig. 6 from Mathews et al., 2016
spinal cord central nervous system myelination decreased occurrence, abnormal control Fig. 6 from Mathews et al., 2016
spinal cord central nervous system myelination occurrence, ameliorated chemical treatment by injection: cholesterol, chemical treatment by environment: U0126 Fig. 6 from Mathews et al., 2016
spinal cord central nervous system myelination occurrence, ameliorated chemical treatment by injection: cholesterol, chemical treatment by environment: sirolimus Fig. 6 from Mathews et al., 2016
spinal cord central nervous system myelination occurrence, ameliorated chemical treatment by injection: cholesterol Fig. 6 from Mathews et al., 2016
spinal cord central nervous system myelination process quality, normal chemical treatment: drug Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte adjacent to dorsal longitudinal fasciculus, normal chemical treatment: drug Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte dorsal to dorsal longitudinal fasciculus, abnormal control Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte mislocalised dorsally, abnormal control Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte position, normal chemical treatment: drug Fig. 5 from Mathews et al., 2014

CITATIONS  (4)